Hepatitis C Virus

Positive Phase Ia Clinical Trial Results For XTL-002 Announced

Published in Hepatitis Weekly, February 4th, 2002

XTL Biopharmaceuticals, Ltd., announced positive clinical data on the antiviral activity and safety of XTL-002, being developed for the treatment of hepatitis C virus (HCV) infections.

Results of the Phase Ia study, which included 15 chronic HCV patients, indicated that HCV viral RNA levels were reduced in over half the patients following a single dose. No serious adverse events were reported.

The single-center study, under the regulation of the United States Food and Drug Administration (FDA) and Ministry of Health, Israel, was designed to test safety, tolerability and efficacy of a single-dose of XTL-002 in chronic HCV patients. The 15 patients...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2002-02-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry